Clearside Biomedical (CLSDQ) Proxy Filing summary

Executive summary

• A special meeting is scheduled for August 29, 2025, to vote on a reverse stock split and corresponding authorized share reduction, with the Board having discretion over the split ratio (1-for-5 to 1-for-15) and timing within 12 months of approval.

• The reverse stock split aims to increase the per-share trading price to maintain Nasdaq Global Market listing, following a notice of non-compliance with the $1.00 minimum bid price requirement.

• The Board may elect not to implement the split if compliance is regained or market conditions change, and only one split ratio will be executed if approved.

• The split will affect all shareholders uniformly, with no material change to ownership percentages or voting power, and cash will be paid in lieu of fractional shares.

• The Board recommends a vote in favor of the proposal, and the outcome will be disclosed in a Form 8-K within four business days after the meeting.

Voting matters and shareholder proposals

• The sole proposal is to approve alternate amendments for a reverse stock split and authorized share reduction, with the Board determining the exact ratio.

• Approval requires a majority of votes cast; abstentions have no effect, and broker non-votes are not expected as the matter is considered routine under NYSE rules.

• Shareholders may vote online, by phone, mail, or in person, and can revoke proxies before the final vote.

• Proposals and director nominations for the 2026 annual meeting must be submitted by specified deadlines and in accordance with bylaw and SEC requirements.

Board of directors and corporate governance

• The Board has full discretion to determine the reverse split ratio and timing, and may abandon the split if deemed unnecessary.

• The Board is not aware of any takeover attempts and states the split is not intended as an anti-takeover measure, though it could have such effects.